Business
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. Neladalkib and zidesamtinib are next-generation tyrosine kinase inhibitors (TKIs). Neladalkib is in development for patients with ALK mutation-positive non-small cell lung cancer (NSCLC) and zidesamtinib is in development for ROS1 mutation-positive NSCLC.
About this update from Nuvalent, Inc.
[{"type":"image","alt":"Royalty Pharma plc","displaySize":"","headline":null,"caption":"Royalty Pharma plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":19,"url":"https://media.zenfs.com/en/globenewswire.com/cfd389aedb614eb79e7cc5d41fbda9e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4OeiHB7vOJ5wAHZW8RfEkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cfd389aedb614eb79e7cc5d41fbda9e7","width":300,"height":19}},"lazy":false},{"type":"text","content":"NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.","length":244,"tagName":"p"},{"type":"text","content":"Neladalkib and zidesamtinib are next-generation tyrosine kinase inhibitors (TKIs). Neladalkib is in development for patients with ALK mutation-positive non-small cell lung cancer (NSCLC) and zidesamtinib is in development for ROS1 mutation-positive NSCLC. Both therapies are designed to deliver a best-in-class combination of efficacy and tolerability.","length":352,"tagName":"p"},{"type":"text","content":"In November 2025, Nuvalent reported positive pivotal results for neladalkib in TKI pre-treated patients which demonstrated durable activity and a generally well-tolerated safety profile. Neladalkib is also being evaluated in an ongoing Phase 3 study in TKI-naïve patients. Zidesamtinib is currently undergoing review by the U.S. Food and Drug Administration and has an action date of September 18, 2026 for TKI pre-treated patients. Zidesamtinib is also being assessed in an ongoing Phase 1/2 study in TKI-naïve patients. Existing analyst consensus projects neladalkib sales to be approximately $3.5 billion and zidesamtinib sales to be approximately $1.9 billion by 2035.","length":672,"tagName":"p"},{"type":"text","content":"Transaction Terms","length":17,"tagName":"p"},{"type":"text","content":"Royalty Pharma is acquiring a low-single digit pre-existing royalty on worldwide net sales on each of Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. The expected royalty duration for both therapies extends through approximately 2041 to 2042.","length":289,"tagName":"p"},{"type":"text","c...